detected by a number of different assays and techniques, most of which utilize either bacterial products or sonicated bacterial cells as antigens (see reference 11 for review). Studies on sera of CF patients with chronic P. aeruginosa respiratory tract infections have demonstrated the presence of humoral antibodies to the extracellular enzymes alkaline protease, elastase, and exotoxin A, using a radioimmunoassay (4, 16) or an enzyme-linked immunosorbent assay (ELISA) (15) . Using crossed immunoelectrophoresis and sonicated bacterial cells, Hoiby and Axelsen (12) detected as many as 22 precipitins in CF patient sera but did not demonstrate protective antibodies. Crossed immunoelectrophoresis has also been used to detect antibodies to a "common antigefl" from P. aeruginosa (13) and, more recently, to lipopolysaccharide (LPS) and to three outer membrane proteins F, H2, and I (17) . However, to measure antibodies necessary to promote Pseudomonas clearance by the host, an assay which could determine antibody titers to bacterial surface-exposed antigenic determinants on intact bacteria might be more appropriate.
Although antibodies against whole Pseudomonlas organisms have been assayed by techniques such as bacterial agglutination or indirect immunofluorescence (see reference 11 for review), a whole bacterial cell ELISA is much more sensitive and quantitative. The use of whole organisms * Corresponding author.
avoids the complications of bacterial antigen purification techniques. In addition, the antigenic orientation of the isolated components may not mimic that observed in the normal state. The whole bacterial cell ELISA technique offers the advantage of measuring antibodies directed to surface-exposed antigenic determinants, both LPS and proteins, when presented in the same steric arrangement and epitope density observed by the host. Therefore, it should more accurately reflect the presence of antibodies which might serve a protective function in vivo. Several investigators have successfully utilized a whole bacterial cell ELISA to quantitate humoral antibody levels to various bacterial cell surface antigens (3, 9, 14) . This study examines the use of a whole bacterial cell ELISA to measure humoral antibody levels to P. aeruginosa.
MATERIALS AND METHODS Bacterial strains and culture conditions. A P. aeruginosa mucoid strain, 144M (obtained from the sputum of a patient with CF), and its spontaneous nonmucoid derivative, 144NM, were maintained on brain heart infusion (BHI) agar ( sample of the cell suspension was removed, serially diluted in PBS, plated onto BHI agar, and incubated overnight at 37°C in 5% C02, and the number of CFU per milliliter was determined.) Formalin was added to the cell suspension to a final concentration of 0.3% formaldehyde, and the cell suspension was maintained at 4°C overnight. The cells were pelleted by centrifugation at 10,000 x g for 10 min at 4TC, washed twice, and resuspended in PBS to a final concentration of 109 CFU/ml. The bacterial suspension was mixed with an equal volume of Freund incomplete adjuvant, and a total of 109 CFU was inoculated intramuscularly in 1.0-ml volumes at two sites. A subsequent injection of 109 CFU was given in the same manner 2 weeks later. Rabbits were bled 2 weeks after the booster, and the immune sera were cQllect- LPS isolation. P. aeruginosa 144M was grown overnight at 37°C, with shaking in 500-ml BHI broth lots; a total of 12 liters was harvested by centrifugation at 10,000 x g for 10 min at 4°C and washed twice with saline; and the pellet was resuspended in distilled water and lyophilized. LPS was isolated from 144M by a recently described protocol of Darveau and Hancock (5) .
Absorption of antisera. Bacteria were grown overnight on BHI agar, swabbed into PBS, pelleted by centrifugation at 10,000 x g for 10 min at 4T, washed twice with saline, and resuspended in PBS to a concentration of 109 bacteria per ml. Formalin was added to the cell suspension to a final concentration of 0.3% formaldehyde, and the cell suspension was incubated at room temperature for 30 min. A total of 100 ml of Formalin-treated bacteria (10" bacteria) was then centrifuged, washed twice with saline, resuspended in 7 ml of PBS, and added to 1 ml of undiluted immune rabbit serum.
The mixture was incubated at 37°C for 1 h with gentle tumbling, and the cells were removed by centrifugation at 20,000 x g for 30 min at 4°C. The supernatant was then used to resuspend a second pellet of bacteria (101" bacteria), and this mixture was incubated overnight at 4°C with tumbling. The absorbed serum was clarified by centrifugation at 20,000 x g for 30 min at 4°C, followed by 0.45-ptm sterile filtration. The absorbed serum was then stored at -70°C in small portions until ready for use.
Immune antiserum was absorbed with purified LPS by mixing sera with an equal volume of LPS solution (5 mg of LPS per ml of distilled water). This mixture was tumbled at 4°C for 24 h. The absorbed serum was clarified by centrifuga- (Fig. 1) or 144NM (Fig. 2) Antiserum raised against either 144M or 144NM produced the highest absorbance values when reacted with its homologous antigen (Fig. 3) . Anti-144M immune serum was found to have a ca. 10-fold-higher antibody titer to 144M than did anti-144N'M immune serum. This might suggest that 144M has immunogenic determinants not present on 144NM or simply a greater number of antigenic determinants than 144NM. In contrast, both anti-144NM and anti-144M immune sera were equally effective against 144NM, suggesting that these strains share many determinants. As expected, nonimmune control serum gave low absorbance readings, all considered to be negative except for that at a 10-1 dilution, which could reflect trace amounts of cross-reacting antibodies to common gram-negative bacterial antigens.
To examine the specificity of immune serum prepared against P. aeruginosa 144M, the antibody titer of anti-144M immune serum for several gram-negative bacteria was determined. In this experiment cuvettes were coated with 2 x 107 CFU of P. aeruginosa 144M, E. coli, K. pneumoniae, or S. marcescens. Anti-144M immune serum had elevated levels of antibodies directed to determinants present on all four strains, when compared with levels of nonimmune control serum (Fig. 4) . This implies that at least some antigens were shared on these four gram-negative microorganisms. When the absolute titers of anti-144M immune serum for each strain were determined, the antibody titer of anti-144M immune serum was at least 10-fold greater for 144M than for any of the three other strains (Table 1) and 812-fold greater than that of nonimmune serum for 144M.
To determine whether this whole cell ELISA can detect antibodies to both LPS and non-LPS surface antigens, anti-144M immune serum was absorbed with either whole 144M organisms or purified 144M LPS. Absorption with whole 144M bacteria removed most antibodies directed at either whole organisms or isolated LPS (Table 2) . Specific absorption with 144M LPS similarly reduced most antibodies directed against LPS but only reduced the anti-144M immune titer to 144M whole cells by one half, which suggests that antibody to surface components other than LPS can be detected by this assay. DISCUSSION
The purpose of this project was to develop an ELISA which could be used to detect and quantitate humoral antibodies directed against cell surface antigens of P. aeruginosa. The major advantage of this method is the ability to 1.0 x 10' 160 a ELISA titers are expressed as the reciprocal of the dilution of serum which gave an absorbance reading of 0.2 and are derived from the data presented in Fig. 4 . VOL. 19, 1984 on January 12, 2018 by guest http://jcm.asm.org/ Downloaded from Rabbits immunized with Formalin-treated, intact P. aeruginosa produced elevated antibody titers to the organism (as compared with the titers of nonimmune rabbits), indicating that the immunocompetent host produces antibodies to P. aeruginosa structures exposed on the bacterial surface. Antiserum raised against either 144M or 144NM produced the highest absorbance values when combined with its homologous antigen. Furthermore, anti-144M immune serum was found to have a ca. 10-fold-higher antibody titer to 144M than did anti-144NM immune serum. This would suggest that 144M has immunogenic determinants not present on 144NM, in agreement with results seen with bactericidal and opsonophagocytic assays described previously (2) . Alternatively, 144M may have similar but quantitatively more immunogenic determinants than 144NM. In contrast, both anti-144NM and anti-144M immune sera were equally effective against 144NM, suggesting that these strains share many determinants. Again, these results are in concert with our earlier findings (2).
Anti-P. aeruginosa 144M immune serum was found to cross-react with strains of E. coli, K. pneumoniae, and S. marcescens. These results demonstrate that P. aeruginosa shares antigens in common with other gram-negative bacteria, perhaps the common antigen described by Hoiby et al. (13) and Sompolinsky et al. (18, 19) . This ELISA can also discern noncommon antigens, however, since the immune titer was always greater for P. aeruginosa than for the other gram-negative bacteria.
Although various immunodiagnostic assays have been described to quantitate antibodies to P. aeruginosa LPS, outer membrane proteins, or extracellular products, this whole cell ELISA enables one to monitor the antibody titer to surface-exposed antigenic determinants on intact organisms. As shown here, this includes antibodies to both LPS and non-LPS surface components. In an earlier study (N. L. Schiller, D. R. Hackley, and A. Morrison, Curr. Microbiol., in press), we determined that 144M LPS is primarily of the "short" or "rough" LPS type, which agrees with the observations of Hancock et al. (10) , who determined that LPSs of strains isolated from patients with CF are often rough LPSs. Although the LPS from 144M is immunogenic, it is not the only major antigenic determinant on 144M, since absorption of anti-144M immune serum with 144M LPS removed only 50% of the antibodies directed to 144M whole bacteria. This result argues for a closer look at other immunogenic surface components, such as outer membrane proteins, for potential candidate vaccine agents for CF patients, an argument recently voiced by Lam et al. (17) .
